Quadrivalent Global Market Report 2024

The quadrivalent market size has grown strongly in recent years. It will grow from $8.28 billion in 2023 to $8.98 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth observed in the historical period can be attributed to factors such as the complexity of diseases, educational initiatives, past health events, overall expansion in healthcare, and technological progress.

The quadrivalent market size is expected to see strong growth in the next few years. It will grow to $12.88 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The anticipated growth in the forecast period can be attributed to factors such as global health events, competitive dynamics, educational campaigns, regulatory changes, and the evolving patterns of diseases. Key trends expected in the forecast period include disease prevalence, the regulatory environment, healthcare infrastructure, consumer awareness and education, and the competitive landscape.

The anticipated rise in the prevalence of chronic and infectious diseases is set to drive the growth of the quadrivalent market. Chronic diseases, attributed to genetics and lifestyle, and infectious diseases caused by agents such as viruses, bacteria, fungi, or protozoa, pose significant health challenges. Quadrivalent vaccines play a crucial role in preventing morbidity and mortality from serious infections, addressing diseases beyond their targeted infections. These vaccines are increasingly employed in preventing chronic diseases associated with infectious agents involved in carcinogenesis. According to the World Health Organization (WHO), 17 million people succumb to chronic or noncommunicable diseases (NCDs) annually, and in 2021, there were an estimated 247 million cases of malaria globally, resulting in approximately 619,000 fatalities. Thus, the escalating prevalence of chronic and infectious diseases is a driving force behind the quadrivalent market's growth.

The expected growth in the quadrivalent market is also fueled by the global expansion of immunization coverage. Immunization coverage, indicating the proportion of a population receiving specific vaccines within a defined period, drives increased demand for vaccines. Quadrivalent vaccines, protecting against four strains, are often integrated into routine vaccination programs to combat multiple disease threats in a single shot. The World Health Organization reported an improvement in the number of zero-dose children, decreasing from 18.1 million in 2021 to 14.3 million in 2022. Moreover, global coverage for the initial dose of the human papillomavirus (HPV) vaccine in girls increased from 16% in 2021 to 21% in 2022. Thus, the rising global immunization coverage is expected to propel the quadrivalent market forward.

A key trend gaining prominence in the quadrivalent market is product innovation. Major companies in the sector are actively developing innovative solutions to reinforce their market positions. AstraZeneca, a UK-based pharmaceutical company, launched FluMist quadrivalent (Influenza Vaccination Live, Intranasal) in September 2022. This FDA-approved nasal-spray flu vaccine for individuals aged 2 to 49 is administered through a needle-free nasal spray. It is available in trivalent or quadrivalent formulations, providing a live attenuated influenza vaccine (LAIV) covered by most health insurance plans and the vaccines for children program.

Major companies in the quadrivalent market are strategically introducing innovative products such as Narcan to drive market revenues. Narcan (naloxone hydrochloride) nasal spray 4 mg is designed to reverse opioid overdoses during a surge in overdose deaths. Sandoz International GmbH, a Germany-based pharmaceutical company, launched Narcan in December 2021. This nasal spray quickly blocks the effects of opioids on the brain, restoring normal breathing and consciousness in individuals experiencing an overdose. It is specifically designed to rapidly reverse the life-threatening effects of an opioid overdose.

In February 2023, China-based biotechnology company Clover Biopharmaceuticals Ltd. entered into a partnership with Adimmune Corporation, a Taiwan-based biopharmaceutical company. This collaboration leverages Adimmune's manufacturing and distribution expertise in providing essential vaccines to Asian populations. Clover aims to strengthen its position as a premier respiratory vaccine franchise and enhance synergies with ongoing COVID-19 vaccine commercialization. As part of this collaboration, Clover will distribute Adimmune's AdimFlu-S (QIS), the only imported quadrivalent influenza vaccination authorized in mainland China, utilizing its established commercial infrastructure.

Major companies operating in the quadrivalent market report are AstraZeneca Plc, Serum Institute of India Private Limited, Sanofi S.A., GlaxoSmithKline Plc, CSL Limited, Bharat Biotech International Limited, Hualan Biological Engineering Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Xenetic Biosciences Inc., Bio Med Pvt. Ltd., Walvax Biotechnology Co. Ltd., Chongqing Zhifei Biological Products Co. Ltd., Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., Biodiem Ltd., Emergent BioSolutions Inc., Biological E. Limited, GSK Biologicals SA, Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products Co. Ltd., Beijing Tian Tan Biological Products Co. Ltd., Shanghai Zhijiang Bio-pharm Co. Ltd., MedImmune, Bio Farma, Butantan Institute, Pasteur Institute of India, China National Biotec Group Co. Ltd. (CNBG).

North America was the largest region in the quadrivalent market in 2023. The regions covered in the quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quadrivalent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of quadrivalent vaccines include intradermal shots, intramuscular injections, and nasal sprays. An intradermal shot involves injecting the vaccine between the epidermis and hypodermis, the top and bottom layers of the skin, as defined by the Center for Disease Control (CDC). These vaccines are formulated using various technologies, including conjugated, live, inactivated, recombinant, toxoid, and others, aiming to immunize against a range of diseases such as cancer, hepatitis, pneumococcal disease, COVID-19, influenza, human papillomavirus, meningococcal disease, polio, rotavirus, and others affecting both pediatric and adult age groups. Distribution channels for these vaccines include hospitals, pharmacies, government suppliers, and other outlets.

The quadrivalent market research report is one of a series of new reports that provides quadrivalent market statistics, including quadrivalent industry global market size, regional shares, competitors with a quadrivalent market share, detailed quadrivalent market segments, market trends and opportunities, and any further data you may need to thrive in the quadrivalent industry. This quadrivalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.